GlassScriptPhysician profile
Lori Jones
NPI 1891990016
$22,359.11
in general payments reported to CMS, 2019-2025
22 companies · $3,298 in 2025
The $3,298 reported for 2025 was more than what 79% of Urogynecology and Reconstructive Pelvic Surgery (Urology) providers received nationally (typical 2025 total: $782).
See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Urology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.64 · 2020: $190 · 2021: $258 · 2022: $9,526 · 2023: $6,591 · 2024: $2,398 · 2025: $3,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,500 · Consulting Fee: $2,500 · Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,500.00 |
| Consulting Fee | $2,500.00 |
| Food and Beverage | $2,287.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $16,500.00 | 2022-2024 | Davinci Xi |
| Gyrus Acmi, INC. | $2,500.00 | 2025 | |
| Boston Scientific Corporation | $880.61 | 2020-2025 | Advantage System, Upsylon, Solyx Sis System |
| Medtronic, INC. | $535.63 | 2021-2025 | Interstim |
| Astellas Pharma US INC | $346.75 | 2019-2024 | Myrbetriq |
| Axonics, INC. | $306.68 | 2023-2024 | Bulkamid, Axonics |
| Dilon Technologies, INC. | $269.60 | 2024-2025 | Hemoblast Bellows |
| Convatec INC. | $201.02 | 2023-2024 | |
| Urovant Sciences INC | $157.22 | 2021-2022 | |
| Abbvie INC. | $126.12 | 2023 | |
| Medtronic USA, INC. | $114.25 | 2020 | |
| Merck Sharp & Dohme LLC | $93.11 | 2019-2023 | Lynparza, Keytruda |
| Coloplast Corp | $82.51 | 2024 | |
| Acerus Pharmaceuticals Corporation | $59.43 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $45.03 | 2023 | Xiaflex, Aveed |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.66 | 2021 | |
| Urogen Pharma, INC. | $23.75 | 2023 | Jelmyto |
| Janssen Biotech, INC. | $20.77 | 2022 | |
| Sumitomo Pharma America, INC. | $20.05 | 2023 | Gemtesa |
| Dendreon Pharmaceuticals LLC | $19.41 | 2019 | |
| Blue Earth Diagnostics | $14.37 | 2019 | |
| Amgen INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.